Tenderloin Clinical Research Foundation
San Francisco, California, 94102, United States
NCT Number: NCT02106702
Each year, there are over 600 unduplicated HIV-infected persons incarcerated in the San Francisco jail. Two thirds of those released with HIV-focused discharge planning are reincarcerated within one year. More than half of HIV-infected jail inmates are diagnosed with mental health conditions severe enough to require medication and a similar proportion report substance use disorders at the time of detention. While some community-based services exist, there remains a critical need to improve linkages to care and adherence to care plans for HIV-infected adults as they move between community and jail. The Navigator Project is a five-year randomized study that will test the effectiveness of an intensive enhanced case management intervention to reduce sex and drug-related HIV transmission risk; increase HIV medication adherence; reduce drug dependence; and reduce reincarceration.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
San Francisco, California, 94102, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
Time frame: 2 months, 6 months, 12 months
change from baseline in self-reported drug and alcohol use, measured by a survey tool, and actual use of five drugs (methamphetamine, cocaine, tetrahydrocannabinol, opiates, and benzodiazepines), measured by a urine screen, at three time points each
Time frame: 12 months
number of times re-detained during the twelve-month study period, collected from jail records
Time frame: 2 months, 6 months, 12 months
change from baseline in self-reported sexual risk behaviors, measured by a survey tool at three time points after the initial detention
Time frame: 2 months, 6 months, 12 months
change from baseline in self-reported adherence (as a %) to antiretroviral therapy, measured by a survey tool at three time points after the initial detention
Time frame: 2 months, 6 months, 12 months
change from baseline in self-reported housing status, measured by a survey tool at three time points after the initial detention
Time frame: 2 months, 6 months,12 months
change from baseline in self-reported insurance coverage, measured by a survey tool at three time points after the initial detention, and use of community health services and jail health services, measured continuously via a community database for 12 months after the initial detention
Time frame: 2 months, 6 months, 12 months
change from baseline in self-reported needle-use and needle-sharing, measured by a survey tool at three time points after the initial detention
University of California, San Francisco
Other
Navigator-Enhanced Case Management for HIV-Infected Jail Inmates Reentering the Community
Acronym: NAV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01235091
Chemically-Induced Disorders, Communicable Diseases
View Trial DetailsNCT04782180
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Miami, Florida, United States
View Trial DetailsNCT05819411
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Boston, Massachusetts, United States
View Trial DetailsNCT05310773
Acquired Immunodeficiency Syndrome, Behavior
Cape Town, Western Cape, South Africa
View Trial Details